Discover ATAI’s pipeline, including promising BPL-003 for TRD, upcoming Phase 3 trials, and a merger with Beckley Psytech.
Results from pritelivir Phase 2 study demonstrate a favorable safety profile and a numerically higher lesion healing rate vs. foscarnetPritelivir Phase 2 results supported FDA Breakthrough Therapy ...
The committee will vote Tuesday on S. 2975, the “PIPELINE Safety Act of 2025,” to reauthorize the Pipeline and Hazardous ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback